T-Cell Therapy is a new immunity that uses specially transformed T-cells to more specifically target cancer cell therapy. T-cell therapy uses immune cells extracted from the patient’s blood to recompile them to identify and attack specific proteins found in brain tumors, and then re-import the immune cells into the patient’s body system. Through genetic modification technology, the targeting, killing activity, and durability of effector T cells are higher than those of conventionally applied immune cells. It can overcome the local immunosuppressive microenvironment of the tumor and break the host’s immune tolerance state. However, this technology also has clinical application risks such as cytokine storms, off-target effects, and insertion mutations.
Global T-cell therapy market estimated to grow with a CAGR of over 12.4% during the forecast period, 2020-2027. It is primarily attributed to factors such as the growing incidence of cancer and the increasing number of patients showing response failure to alternative treatments. Additionally, investments by government bodies are comparatively less in throat cancer, and brain tumor segment will accelerate the growth of the global T-cell therapy market in the upcoming periods. Moreover, the upsurge in the number of adults and children developing cancer would lead to the robust growth of the global T-cell therapy market size in the forecast span. At present, T-cell therapy has been approved by the US Food and Drug Administration (FDA) as some refractory non-Hodgkin lymphoma (refractory non-Hodgkin lymphoma), and childhood relapsed acute lymphoblastic leukemia (pediatric relapsed acute lymphoblastic leukemia, ALL) standard of care.
With the approval of Kymriah and Yescarta by FAD, various companies started to develop small molecule and protein-based therapies to adoptive T cell therapy. Further, clinical success and accelerated product approvals projected to drive the global T-cell therapy market industry. The growing demand for t-cell therapy in patients with blood cancer or hematologic cancer through acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphomas will promulgate the t-cell therapy market share in the upcoming periods. Hematological tumors are developing steadily. Solid tumors are seeking breakthroughs. Due to the unique properties and target specificities of hematological tumors, T cell therapy has made significant breakthroughs in the treatment of hematological malignant tumors and demonstrated strong strength.
T-cell therapy is one of the best immunotherapies today. Although it has a unique effect on hematological malignancies, the shortcomings of this therapy are also obvious. T-cell therapy is currently targeting hematological tumors and is still helpless to solid tumors, but most tumors are solid tumors. Fortunately, the fourth-generation T-cell therapy has already experimented with solid tumors. T-cell therapy uses genetically modified immune cells to kill tumors. It has become a life-saving medicine for a large number of patients with lymphoma and leukemia to relieve their pain.
According to WHO, the second leading cause of death globally is cancer that responsible for an estimated 9.6 million deaths in 2018. The global cancer burden is projected to have risen from 9.6 million deaths in 2018 and 18.1 million new cases.
Based on therapy, the global t-cell therapy market classified into CAR T-Cell Therapy, T Cell Receptor (TCR), and Tumor-Infiltrating Lymphocytes. The CAR T-Cell Therapy segment predicted to gain a major in the t-cell therapy market by 2027. It is owing to the growing demand for efficient cancer treatment models coupled with CAR-T cell therapy that uses genetically modified immune cells to kill tumors and has become a life-saving medicine for a large number of patients with lymphoma and leukemia to relieve their pain.
The T Cell Receptor (TCR) segment will drive with a significant rate in the forecast period as it is used to recognize a tumor-specific protein fragment/MHC combination.
Based on modality, the global t-cell therapy market bifurcated into Research and Commercialized. The research segment projected to generate maximum revenue in the market by 2027. It is due to most of the products of t-cell therapy that are under the clinical investigation stage along with the large number of research centers considering it as a profitable method of cancer management in the upcoming years.
The Commercialized segment will be the fastest-growing segment in the forecast period owing to the rules and regulatory agencies providing license and provide support for the commercialization of t-cell therapy.
Based on indication, the global t-cell therapy market classified into Hematologic Malignancies (Lymphoma, Leukemia, and Myeloma) and Solid Tumors (Melanoma, Brain & Central Nervous System, Liver cancer, and others). The Hematologic Malignancies witnessed a higher share in 2019 and estimated to dominate the t-cell therapy market by 2027. It is due to t-cell used for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, and multiple myeloma. It is used for recognizing and eliminating cancer cells.
Solid Tumors will grow with a momentous rate during the forecast period owing to t-cell therapy used in the treatment of including melanoma, breast cancer, and sarcoma.
Based on geography, the global T-Cell Therapy market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America estimated to occupy the lion’s share in the t-cell therapy by 2027, owing to the presence of a large number of research centers and the rise in the incidence of cancer in the USA.
The European market will influence during the forecast periods due to the approval of CAR T-cell Therapy products along with the presence of key players in these regions.
Companies such as Novartis AG, Gilead Sciences, bluebird bio, TCR2 Therapeutics Inc., Sorrento Therapeutics, Kite Pharma, Merck KGaA, Pfizer, Amgen, Celgene Corporation and Fate Therapeutics are the key players in the Global T-Cell Therapy Market.
By Therapy Type